TY - JOUR
T1 - Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig i acute HIV infection brief-communication
AU - The RV411 study group
AU - Colby, Donn J.
AU - Trautmann, Lydie
AU - Pinyakorn, Suteeraporn
AU - Leyre, Louise
AU - Pagliuzza, Amélie
AU - Kroon, Eugène
AU - Rolland, Morgane
AU - Takata, Hiroshi
AU - Buranapraditkun, Supranee
AU - Intasan, Jintana
AU - Chomchey, Nitiya
AU - Muir, Roshell
AU - Haddad, Elias K.
AU - Tovanabutra, Sodsai
AU - Ubolyam, Sasiwimol
AU - Bolton, Diane L.
AU - Fullmer, Brandie A.
AU - Gorelick, Robert J.
AU - Fox, Lawrence
AU - Crowell, Trevor A.
AU - Trichavaroj, Rapee
AU - O'Connell, Robert
AU - Chomont, Nicolas
AU - Kim, Jerome H.
AU - Michael, Nelson L.
AU - Robb, Merlin L.
AU - Phanuphak, Nittaya
AU - Ananworanich, Jintanat
AU - Phanuphak, P.
AU - Teeratakulpisarn, N.
AU - Chottanapund, S.
AU - De Souza, M.
AU - Fletcher, J.
AU - Tantivitayakul, P.
AU - Eamyoung, P.
AU - Sutthichom, D.
AU - Prueksakaew, P.
AU - Puttamaswin, S.
AU - Tipsuk, S.
AU - Benjapornpong, K.
AU - Ratnaratorn, N.
AU - Munkong, C.
AU - Tanjnareel, K.
AU - Kanaprach, R.
AU - Rerknimitr, R.
AU - Wattanaboonyongcharoen, P.
AU - Rojnuckarin, P.
AU - Manasnayakorn, S.
AU - Schuetz, A.
AU - Akapirat, S.
N1 - Funding Information:
We are grateful to the participants who have made this research possible. We thank T. Schacker for providing data on the lymph nodes from one participant. This work was supported by the NIH grant R01AI108433, a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the U.S. Department of Defense (DoD), the Division of AIDS at the U.S. National Institute of Allergy and Infectious Diseases, and by an intramural grant from the Thai Red Cross AIDS Research Centre. The US Army Medical Research Acquisition Activity (820 Chandler Street, Fort Detrick, MD 21702-5014, USA) is the awarding and administering acquisition office for the cooperative agreement. It is also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. Antiretroviral therapy was supported by the Thai Government Pharmaceutical Organization, Gilead, Merck and ViiV Healthcare. The views expressed are those of the authors. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, the US Army, or the Department of Defense, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government, including the US National Institutes of Health.
Publisher Copyright:
© 2018 The Author(s).
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after analytical treatment interruption. We show that 8 participants, who initiated treatment during Fiebig I and were treated for a median of 2.8 years, all experienced rapid viral load rebound following analytical treatment interruption, indicating that additional strategies are required to control or eradicate HIV.
AB - Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after analytical treatment interruption. We show that 8 participants, who initiated treatment during Fiebig I and were treated for a median of 2.8 years, all experienced rapid viral load rebound following analytical treatment interruption, indicating that additional strategies are required to control or eradicate HIV.
UR - http://www.scopus.com/inward/record.url?scp=85048313622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048313622&partnerID=8YFLogxK
U2 - 10.1038/s41591-018-0026-6
DO - 10.1038/s41591-018-0026-6
M3 - Article
C2 - 29892063
AN - SCOPUS:85048313622
VL - 24
SP - 923
EP - 926
JO - Nature Medicine
JF - Nature Medicine
SN - 1078-8956
IS - 7
ER -